Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic
stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and
homoharringtonine, which exhibited a anticancer mechanism and has been widely used in
patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these
agents has not been elucidated in children with JMML. The primary objective is to assess the
treatment effect on response rate in this subject population.
Phase:
N/A
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University
Collaborators:
Children's Hospital of Hebei Province Qilu Hospital of Shandong University Taian City Central Hospital The Affiliated Hospital of Qingdao University The Second Hospital of Hebei Medical University